EXEL vs. BMY
Compare and contrast key facts about Exelixis, Inc. (EXEL) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: EXEL or BMY.
Correlation
The correlation between EXEL and BMY is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
EXEL vs. BMY - Performance Comparison
Key characteristics
EXEL:
1.67
BMY:
0.31
EXEL:
2.51
BMY:
0.69
EXEL:
1.35
BMY:
1.09
EXEL:
0.98
BMY:
0.20
EXEL:
9.22
BMY:
1.18
EXEL:
6.27%
BMY:
8.16%
EXEL:
34.69%
BMY:
30.79%
EXEL:
-97.38%
BMY:
-70.62%
EXEL:
-27.43%
BMY:
-29.64%
Fundamentals
EXEL:
$9.88B
BMY:
$103.18B
EXEL:
$1.76
BMY:
-$4.41
EXEL:
2.27
BMY:
1.15
EXEL:
$1.74B
BMY:
$36.44B
EXEL:
$1.69B
BMY:
$23.27B
EXEL:
$650.08M
BMY:
$11.69B
Returns By Period
In the year-to-date period, EXEL achieves a 7.33% return, which is significantly higher than BMY's -7.23% return. Over the past 10 years, EXEL has outperformed BMY with an annualized return of 27.74%, while BMY has yielded a comparatively lower 0.80% annualized return.
EXEL
7.33%
-2.48%
36.20%
56.69%
14.47%
27.74%
BMY
-7.23%
-12.05%
-0.38%
11.56%
0.73%
0.80%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
EXEL vs. BMY — Risk-Adjusted Performance Rank
EXEL
BMY
EXEL vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Exelixis, Inc. (EXEL) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
EXEL vs. BMY - Dividend Comparison
EXEL has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.75%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
EXEL Exelixis, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 4.75% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% |
Drawdowns
EXEL vs. BMY - Drawdown Comparison
The maximum EXEL drawdown since its inception was -97.38%, which is greater than BMY's maximum drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for EXEL and BMY. For additional features, visit the drawdowns tool.
Volatility
EXEL vs. BMY - Volatility Comparison
Exelixis, Inc. (EXEL) and Bristol-Myers Squibb Company (BMY) have volatilities of 9.64% and 10.10%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Financials
EXEL vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Exelixis, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities